127 related articles for article (PubMed ID: 17485552)
1. Gene-expression analysis identifies novel RBL2/p130 target genes in endemic Burkitt lymphoma cell lines and primary tumors.
De Falco G; Leucci E; Lenze D; Piccaluga PP; Claudio PP; Onnis A; Cerino G; Nyagol J; Mwanda W; Bellan C; Hummel M; Pileri S; Tosi P; Stein H; Giordano A; Leoncini L
Blood; 2007 Aug; 110(4):1301-7. PubMed ID: 17485552
[TBL] [Abstract][Full Text] [Related]
2. Genetic alterations of the retinoblastoma-related gene RB2/p130 identify different pathogenetic mechanisms in and among Burkitt's lymphoma subtypes.
Cinti C; Leoncini L; Nyongo A; Ferrari F; Lazzi S; Bellan C; Vatti R; Zamparelli A; Cevenini G; Tosi GM; Claudio PP; Maraldi NM; Tosi P; Giordano A
Am J Pathol; 2000 Mar; 156(3):751-60. PubMed ID: 10702389
[TBL] [Abstract][Full Text] [Related]
3. Retinoblastoma-related geneRb2/p130 are rarely mutated in Burkitt's lymphoma from Brazil.
Klumb CE; Magluta EP; Rezende LM; Apa AG; Alonso JF; Maia RC
Am J Hematol; 2007 Mar; 82(3):238-9. PubMed ID: 16955460
[TBL] [Abstract][Full Text] [Related]
4. Promoter Methylation Status Modulate the Expression of Tumor Suppressor (RbL2/p130) Gene in Breast Cancer.
Ullah F; Khan T; Ali N; Malik FA; Kayani MA; Shah ST; Saeed M
PLoS One; 2015; 10(8):e0134687. PubMed ID: 26271034
[TBL] [Abstract][Full Text] [Related]
5. RBL2/p130 is a direct AKT target and is required to induce apoptosis upon AKT inhibition in lung cancer and mesothelioma cell lines.
Pentimalli F; Forte IM; Esposito L; Indovina P; Iannuzzi CA; Alfano L; Costa C; Barone D; Rocco G; Giordano A
Oncogene; 2018 Jul; 37(27):3657-3671. PubMed ID: 29606701
[TBL] [Abstract][Full Text] [Related]
6. High incidence of allelic loss at 16q12.2 region spanning RBL2/p130 gene in retinoblastoma.
Priya K; Jada SR; Quah BL; Quah TC; Lai PS
Cancer Biol Ther; 2009 Apr; 8(8):714-7. PubMed ID: 19252413
[TBL] [Abstract][Full Text] [Related]
7. Genetic alterations disrupting the nuclear localization of the retinoblastoma-related gene RB2/p130 in human tumor cell lines and primary tumors.
Cinti C; Claudio PP; Howard CM; Neri LM; Fu Y; Leoncini L; Tosi GM; Maraldi NM; Giordano A
Cancer Res; 2000 Jan; 60(2):383-9. PubMed ID: 10667591
[TBL] [Abstract][Full Text] [Related]
8. Deep sequencing of MYC DNA-binding sites in Burkitt lymphoma.
Seitz V; Butzhammer P; Hirsch B; Hecht J; Gütgemann I; Ehlers A; Lenze D; Oker E; Sommerfeld A; von der Wall E; König C; Zinser C; Spang R; Hummel M
PLoS One; 2011; 6(11):e26837. PubMed ID: 22102868
[TBL] [Abstract][Full Text] [Related]
9. pRb2/p130 protein expression and RBL2 mutation analysis in Burkitt lymphoma from Uganda.
Kalungi S; Steine SJ; Wabinga H; Bostad L; Molven A
BMC Clin Pathol; 2009 Aug; 9():6. PubMed ID: 19691827
[TBL] [Abstract][Full Text] [Related]
10. Gene expression analysis uncovers similarity and differences among Burkitt lymphoma subtypes.
Piccaluga PP; De Falco G; Kustagi M; Gazzola A; Agostinelli C; Tripodo C; Leucci E; Onnis A; Astolfi A; Sapienza MR; Bellan C; Lazzi S; Tumwine L; Mawanda M; Ogwang M; Calbi V; Formica S; Califano A; Pileri SA; Leoncini L
Blood; 2011 Mar; 117(13):3596-608. PubMed ID: 21245480
[TBL] [Abstract][Full Text] [Related]
11. Cyclin F drives proliferation through SCF-dependent degradation of the retinoblastoma-like tumor suppressor p130/RBL2.
Enrico TP; Stallaert W; Wick ET; Ngoi P; Wang X; Rubin SM; Brown NG; Purvis JE; Emanuele MJ
Elife; 2021 Dec; 10():. PubMed ID: 34851822
[TBL] [Abstract][Full Text] [Related]
12. The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma.
Wagener R; Seufert J; Raimondi F; Bens S; Kleinheinz K; Nagel I; Altmüller J; Thiele H; Hübschmann D; Kohler CW; Nürnberg P; Au-Yeung R; Burkhardt B; Horn H; Leoncini L; Jaffe ES; Ott G; Rymkiewicz G; Schlesner M; Russell RB; Klapper W; Siebert R
Blood; 2019 Feb; 133(9):962-966. PubMed ID: 30567752
[TBL] [Abstract][Full Text] [Related]
13. The RB (pRb2/p16) and p53 (p14/p53/p21) tumor-suppressor pathways in endemic Burkitt lymphoma.
Kalungi S; Wabinga H; Bostad L
J Pediatr Hematol Oncol; 2011 Mar; 33(2):e54-9. PubMed ID: 21127431
[TBL] [Abstract][Full Text] [Related]
14. FGFR1 Is Critical for RBL2 Loss-Driven Tumor Development and Requires PLCG1 Activation for Continued Growth of Small Cell Lung Cancer.
Kim KB; Kim Y; Rivard CJ; Kim DW; Park KS
Cancer Res; 2020 Nov; 80(22):5051-5062. PubMed ID: 32973083
[TBL] [Abstract][Full Text] [Related]
15. Nucleosomes positioning around transcriptional start site of tumor suppressor (Rbl2/p130) gene in breast cancer.
Farman FU; Iqbal M; Azam M; Saeed M
Mol Biol Rep; 2018 Apr; 45(2):185-194. PubMed ID: 29417345
[TBL] [Abstract][Full Text] [Related]
16. miR‑29 promoter and enhancer methylation identified by pyrosequencing in Burkitt lymhoma cells: Interplay between MYC and miR‑29 regulation.
Mazzoccoli L; Robaina MC; Bacchi CE; Soares Lima SC; Klumb CE
Oncol Rep; 2019 Aug; 42(2):775-784. PubMed ID: 31173259
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus core protein modulates pRb2/p130 expression in human hepatocellular carcinoma cell lines through promoter methylation.
Mileo AM; Mattarocci S; Matarrese P; Anticoli S; Abbruzzese C; Catone S; Sacco R; Paggi MG; Ruggieri A
J Exp Clin Cancer Res; 2015 Nov; 34():140. PubMed ID: 26576645
[TBL] [Abstract][Full Text] [Related]
18. Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.
Modi S; Kubo A; Oie H; Coxon AB; Rehmatulla A; Kaye FJ
Oncogene; 2000 Sep; 19(40):4632-9. PubMed ID: 11030152
[TBL] [Abstract][Full Text] [Related]
19. MiR-29 silencing modulates the expression of target genes related to proliferation, apoptosis and methylation in Burkitt lymphoma cells.
Mazzoccoli L; Robaina MC; Apa AG; Bonamino M; Pinto LW; Queiroga E; Bacchi CE; Klumb CE
J Cancer Res Clin Oncol; 2018 Mar; 144(3):483-497. PubMed ID: 29318382
[TBL] [Abstract][Full Text] [Related]
20. Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma.
Kleo K; Dimitrova L; Oker E; Tomaszewski N; Berg E; Taruttis F; Engelmann JC; Schwarzfischer P; Reinders J; Spang R; Gronwald W; Oefner PJ; Hummel M
BMC Cancer; 2019 Apr; 19(1):322. PubMed ID: 30953469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
